In the wake of Adidas’ rise in the sports apparel industry, Nike and Under Armour are feeling the heat.
While Nike can be regarded as a veteran, with Under Armour catching up in terms of brand value and sponsorships, it is only fair to pit these two companies against each other.
Under Armour needs new armor
Under Armour has been showcasing impressive revenue growth since its 2005 IPO. Back then it was referred to as a Wall Street darling, often even touted as ‘the next Nike.’
However, the brand failed to maintain its charisma in the course of the last decade.
With North America making up a chunk of its core market — about 75% of sales — this dependence has started to cost Under Armour with performance in the geography on the decline. This led to Under Armour reporting its first-ever net loss during the second quarter of 2017. Just when Under Armour was fighting for its survival, things got worse as its key retail distributors like Sports Authority and Sports Chalet filed for bankruptcy.
Under Armour’s signature shoe Curry 4 that created a lot of hype suffered not only from manufacturing delays but also received some bad reviews. This led to the exit of Peter Ruppe, Under Armour’s chief footwear executive.
The performance gear maker also failed to maintain its business in the crucial overseas markets like China — where Nike has managed to stay ahead in this game.
Nike, still checking a few boxes
China has grown to become Nike’s second largest market. This growth is estimated to help the sports giant survive in the ever-challenging industry of sportswear.
Nike, that made a bold promise of generating close to $50 billion annual revenue by 2020, has been one of those consistent performers. The industry veteran has managed to put up a steady growth in its revenue.
Nike is not losing it so soon to its bigtime rival Adidas. It is working on ramping up its innovation department — something to go hand in hand with its strong management team as well as daring marketing strategies.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on